Globus Medical, Inc. GMED
Composite 69/100; the shares have moved about 38% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 40/100 — a slight mark against it.
Balance-sheet strength ranks 90/100 — a strong point in its favour. Growth ranks 88/100 — a strong point in its favour. Quality ranks 73/100 — a moderate point in its favour.
Momentum ranks 40/100 — a slight mark against it.
What the company does Globus Medical designs, manufactures, and markets musculoskeletal disorder solutions spanning spine, trauma, joint arthroplasty, neuromonitoring, and motion preservation technologies. Its portfolio includes traditional fusion implants, motion-preservation devices, interventional vertebral fracture treatments, and biologics.
Key financials Gross margin 68.5%, operating margin 21.3%, net margin 18.9%. ROE 13.3%, ROA 8.2%, ROCE 12.1%. Revenue grew 27.0% and EPS 66.7%. Debt/Equity 0.02, current ratio 4.56, Piotroski F-Score 8/9, Altman Z 10.51.
Stock health 12-month momentum +48.52%, but -20.85% from 52-week high; RSI(14) 53.30. Strength pillar score 94.9/100 signals robust competitive position.
Price vs fair value The stock trades at a discount to both our fair-value estimate and analyst targets. - Price is at a 21.80% discount to the fair-value estimate of 97.75 (Simply Wall St). - Price is at a 29.48% discount to the 12-month target of 103.92 (analyst count 13.0). - Simply Wall St notes undervaluation ahead of earnings (Simply Wall St). - Peer ISRG highlighted as “best house on the block” with premium valuation (Trefis).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.